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Erlotinib is highly effective in lung cancer patients with epidermal growth
factor receptor (EGFR) mutations. However, despite initial favorable
responses, most patients rapidly develop resistance to erlotinib soon after
the initial treatment. This study aims to identify new genes and pathways
associated with erlotinib resistance mechanisms in order to develop novel
therapeutic strategies. Here, we induced knockout (KO) mutations in erlo-
tinib-resistant human lung cancer cells (NCI-H820) using a genome-scale
CRISPR-Cas9 sgRNA library to screen for genes involved in erlotinib sus-
ceptibility. The spectrum of sgRNAs incorporated among erlotinib-treated
cells was substantially different to that of the untreated cells. Gene set
analyses showed a significant depletion of ‘cell cycle process’ and ‘protein
ubiquitination pathway’ genes among erlotinib-treated cells. Chemical inhi-
bitors targeting genes in these two pathways, such as nutlin-3 and carfil-
zomib, increased cancer cell death when combined with erlotinib in both
in vitro cell line and in vivo patient-derived xenograft experiments. There-
fore, we propose that targeting cell cycle processes or protein ubiquitina-
tion pathways are promising treatment strategies for overcoming resistance
to EGFR inhibitors in lung cancer.
Abbreviations
ATCC, American Type Culture Collection; edgeR, bioconductor software package for examining differential expression of replicated count
data; EGFR, epidermal growth factor receptor; GeCKO, genome-scale CRISPR/Cas9 knockout; HGF, hepatocyte growth factor; MAGeCK-
VISPR algorithm, comprehensive quality control analysis and visualization pipeline for CRISPR/Cas9 screens based on MAGeCK VISPR;
MOI, multiplicity of infection; NSCLC, non-small-cell lung cancer; SCLC, small cell lung cancer; sgRNA, single-guide RNA; TKIs, tyrosine
kinase inhibitors.
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1. Introduction
Lung cancer is the most commonly diagnosed cancer
in the world and a leading cause of cancer-related
deaths [1]. A number of new targeted therapies have
been developed for lung cancers with mutations in
specific genes, such as epidermal growth factor recep-
tor (EGFR), which is known to control cell growth
and proliferation [2]. Mutations of this receptor can
lead to activation of downstream signaling cascades
such as cell proliferation, apoptosis, and migration,
thus contributing to tumorigenesis and metastasis [3].
Many tyrosine kinase inhibitors (TKIs) have been
developed to suppress the tumor-promoting properties
caused by EGFR mutations in non-small-cell lung can-
cer (NSCLC) patients [4,5]. Among the EGFR-target-
ing TKIs, erlotinib is widely used for both localized
and metastatic NSCLC patients [6,7] because it has
relatively few side effects and high efficacy [8]. How-
ever, many patients subsequently develop resistance to
erlotinib treatment.
The mechanism of acquired resistance to first-gener-
ation EGFR-TKIs (such as erlotinib) is the occurrence
of a secondary EGFR kinase domain mutation, such
as the T790M substitution in exon 20—which accounts
for about half of the erlotinib-resistant cases [9]. Other
genomic mutations in tumor cells that may contribute
to EGFR-TKIs resistance include amplification of the
MET oncogene [10], overexpression of hepatocyte
growth factor (HGF), amplification of the ERBB2
gene [11], aberrant downstream pathways (e.g., AKT
mutations and PTEN loss), impairment of the EGFR-
TKIs-mediated apoptosis pathway (e.g., BCL2L11/
BIM deletion polymorphism), and histological trans-
formation to small cell lung cancer (SCLC) [9].
Increasing the survival benefits from first-line treat-
ments in NSCLC patients with EGFR mutations and
delaying the occurrence of resistance are two critical
tasks that could be solved by EGFR-TKI-based com-
bination therapies, including combinations with vari-
ous chemo-agents, targeted cancer drugs, and even
immunotherapeutic methods.
Genetic screening using CRISPR-Cas9 can be used
for rapidly identifying driver genes associated with vari-
ous hallmarks of cancer progression [12]. The CRISPR-
Cas9 system is based on RNA-guided nucleases where a
single-guide RNA (sgRNA) directs the Cas9 nuclease to
cause double-stranded cleavage of matching target
DNA sequences [13]. The ease of retargeting Cas9 by
simply designing short guide RNA sequences to every
human gene enables large-scale unbiased genome per-
turbation experiments that probe gene function or
identify causal genetic variants [14]. The genome-wide
screen of loss of function previously used an RNAi-
based approach, but this approach only causes partial
knockdown, has extensive off-target effects, and is lim-
ited to transcribed genes [15]. By contrast, Cas9-medi-
ated pooled sgRNA screens have provided enhanced
screening sensitivity as well as consistency and can be
designed to target nearly any DNA sequence [16,17].
Here, we performed a CRISPR-Cas9 loss-of-func-
tion screening experiment followed by sgRNA
sequencing to identify genes whose knockout restores
erlotinib sensitivity in an erlotinib-resistant lung cancer
cell line. Our sgRNA screen shows cell cycle processes
and ubiquitin regulation pathways as specific biologi-
cal processes that can sensitize erlotinib-resistant cells.
Furthermore, our in vitro and in vivo data showed a
synergistic anticancer effect of chemical inhibitors for
specific genes in these two pathways, when used in
combination with erlotinib. These findings suggest that
combination therapies that include chemical inhibitors
to cell cycle processes and ubiquitin regulation path-
ways can serve as novel treatment strategies to over-
come erlotinib resistance for EGFR mutant patients
with NSCLC.
2. Materials and methods
2.1. Cell culture and reagents
Human lung cancer cell lines (NCI-H820, NCI-H1975)
were purchased from the American Type Culture Col-
lection (ATCC). All cell lines were cultured as previ-
ously described [18], and mycoplasma testing was
routinely performed using e-MycoTM plus Mycoplasma
PCR Detection Kit (Intron, Korea), verifying that the
cells were mycoplasma free. Anti-PARP, anticleaved
caspase 3, anti-AKT, anti-phospho-AKT, anti-ERK,
and anti-phospho-ERK antibodies were purchased
from Cell Signaling Technology. Erlotinib, SJ-172550,
nutlin-3, and carfilzomib were obtained from APEx-
BIO. Bortezomib, quinacrine, brefeldin A, and oua-
bain were purchased from Selleckchem (Houston, TX,
USA), and N-ethylmaleimide was obtained from the
Sigma-Aldrich Corporation (Sigma, St. Louis, MO,
USA).
2.2. Lentiviral library amplification and cell
transduction
The human GeCKO lentiviral pooled library, lenti-
CRISPR v2, was purchased from Addgene (Water-
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town, MA, USA) (cat # 1000000048) as two half-li-
braries (A and B). The library was amplified according
to the manufacturer’s recommendations [17]. Briefly,
the library plasmid DNA were transformed using elec-
troporation in Endura electrocompetent cells (Lucigen,
Middleton, WI, USA). Colonies were recovered from
the plates, and plasmid DNA was extracted using the
Endotoxin-Free Plasmid Maxiprep kit (Qiagen, Ger-
mantown, MD, USA).
To produce lentivirus, twelve T-75 flasks of 293FT
cells (Invitrogen, Carlsbad, CA, USA) were seeded
at ~ 70 % confluence the day before transfection in
D10 media (DMEM supplemented with 10 % fetal
bovine serum). During the transfection, media was
removed and 4 mL of prewarmed reduced serum Opti-
MEM media (Gibco, Waltham, MA, USA) was added
to each flask. Transfection was performed using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA, USA). For
each flask, plasmid DNA were cotransfected with 6 lg
of lentiCRISPRv2 half-library A or B with 3 lg of
pCMV-VSVg and 4.5 lg of psPAX2 (Addgene) in
293FT cell. The complete mixture was incubated for
15 min before being added to cells. After 6 h, the
media was changed to 12 mL D10 supplemented.
After 48 h, supernatants from the transfected 293FT
cells were harvested and centrifuged at 3000 rpm at
4 °C for 10 min to remove pellet cell debris. The
supernatant was concentrated using Lenti-X concen-
trator (Clontech, Mountain View, CA, USA) accord-
ing to the manufacturer’s protocol. Pooled lentiviral
libraries are transduced to 1 9 108 NCI-H820 cells
with 3 9 106 cells plated per transduction well. The
multiplicity of infection (MOI) is about 0.3–0.4 to
insure that most cells receive only one stably inte-
grated RNA guide. To select the cells containing
sgRNA, 1 lgmL1 puromycin was added to cells for
3 days. The GeCKO v2 libraries target 19,050 human
coding genes with 6 sgRNAs per gene [19], and each
group contained at least 1.2 9 107 cells (coverage
100x).
2.3. Negative screening of erlotinib-resistant
cells
Freshly prepared NCI-H820 cells (~2 9 107 cells) con-
taining GeCKO libraries were split into three plates
with each portion containing a minimum of 3 9 106
cells. The first portion were frozen down for genomic
DNA analysis to profile the sgRNA diversity after
transfection (D0), the second portion cultured in
DMSO without erlotinib for 7 (D7) or 14 days (D14)
as control samples, and the third portion cultured with
1 lM erlotinib for 7 (E7) or 14 days (E14). Erlotinib-
treated cells and control cells were passaged in fresh
media with and without 1 lM erlotinib, respectively.
At this time, the IC50 of NCI-H820 cells for erlotinib
was more than 100 lM. The screening experiment was
performed in duplicate. All samples were subjected to
sgRNA sequencing as follows.
2.4. sgRNA sequencing and data analysis
Frozen cell pellets were thawed, and genomic DNA
was extracted with a Blood & Cell Culture Midi kit
(Qiagen). The amplification of sgRNA target
sequences for deep sequencing was performed as
described [17]. All PCR products obtained from each
sample were run on an agarose gel, gel-extracted, and
purified according to the manufacturer’s recommenda-
tions.
The resulting libraries were sequenced with single-
end 100-bp reads on a HiSeq2500 (Illumina, San
Diego, CA, USA). Raw sequencing data were prepro-
cessed using the fastx toolkit (http://hannonlab.cshl.ed
u/fastx_toolkit/) which included the fastq_quality_filter
to remove low-quality reads. Resulting reads were
trimmed to remove the constant portion of the sgRNA
sequences with CRISPR.sgRNA_read_trimmer in the
GenePattern Module Archive (http://www.gparc.org/)
and then aligned to the GeCKO v2 sgRNA library
using bowtie 1 (v1.1.1) under default settings. After
alignment, the number of uniquely aligned reads for
each library sequence was calculated by CRISPR.sin-
gle_sgRNA_count in GParc. The raw read counts were
normalized as follows: normalized reads per sgRNA =
(reads per sgRNA/total reads for all sgRNAs in sam-
ple) 9 106 + 1.
In our negative selection screening, we looked for
sgRNAs whose number gets depleted in 14 days of
erlotinib treatment. Thus, we filtered out sgRNAs that
had zero read count in 14 days of DMSO treatment
(i.e. without erlotinib treatment). Then, we calculated
the ‘beta score’ that represents the extent of selection
in a manner similar to the term of ‘log fold-change’
using MAGeCK-VISPR (https://bitbucket.org/liulab/
mageck-vispr) program. The MAGeCK-VISPR algo-
rithm compares the sgRNA abundance of all sgRNAs
targeting a gene across different conditions and assigns
each gene a beta score of essentialities in each condi-
tion compared with the controls. We used the cells at
day 0 (D0) as the control samples in calculating the
beta score. Genes with beta scores among the highest
and lowest 2% were selected as differential between
control and treatment samples, and these genes were
further subjected to k-means clustering. Alternatively,
we also obtained the differentially expressed sgRNAs
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between cells at 14 days of DMSO (D14) or erlotinib
treatment (E14) using edgeR (version 3.4.2) with the
normalized read counts. We applied both the differen-
tial expression (FDR < 0.05 and log2FoldChange <
1) and the abundance (number of sgRNAs per
gene>= 2) criteria to screen for differential sgRNAs.
2.5. Functional enrichment and survival analyses
Cytoscape StringApp version 1.5.0 (http://apps.cytosca
pe.org/apps/stringapp) was used for network expan-
sion [20] and functional enrichment analysis. Starting
with the 81 top candidate genes obtained from sgRNA
screening, we obtained the expanded network using a
confidence score of 0.4 (medium confidence) and the
maximum number of interactions to 5 best scoring
hits. Then, we used the functional enrichment analysis
module in STRING to obtain over-represented terms
of the expanded network nodes in the gene ontology
(GO) terms for biological processes. In addition, we
also computed the GO enriched terms for 81 top can-
didate genes using the MSigDB (version 6.2) analysis
tool (http://software.broadinstitute.org/gsea/index.jsp)
with an FDR cutoff of < 0.05 [21]. As for the survival
analysis, we used the OncoLnc website (http://www.
oncolnc.org/) to perform Kaplan–Meier analyses with
the P-value of log-rank test < 0.05 for the TCGA lung
adenocarcinoma (LUAD) cohort.
2.6. Validation of the five candidate genes using
CRISPR/cas9 sgRNA
For erlotinib-sensitive validation study, we produce
lentiCRISPR with sgRNAs targeting five candidate
genes and one nontargeting control (sgNTC). The
sgRNA sequence referred to the human GeCKO len-
tiviral pooled library sequence (Table S1). The erloti-
nib sensitivity was measured by in vitro cytotoxicity
assay. Cell survival at different erlotinib doses was
determined by EzCytox WST assay kit (Daeil Lab,
Seoul, Korea) and mRNA quantification using real-
time PCR.
2.7. In vitro cytotoxicity assay
For the cell viability assays, approximately 5000 cells
were plated in each well of a 96-well plate and incu-
bated at 37 °C with 5% CO2 for 1 day then added with
the indicated drugs in triplicate at serially diluted con-
centrations with 100 lL medium, respectively. Cells
were treated with the following reagents at the indi-
cated final concentration: erlotinib (50 mM), SJ-172550
(100 mM), nutlin-3 (100 mM) carfilzomib (10 mM),
bortezomib (20 mM), quinacrine (100 mM), brefeldin
A (1 mM), and ouabain (100 mM) for 72 h and exam-
ined for cell viability using the EzCytox WST assay kit.
Cell viabilities were estimated as relative values com-
pared to the untreated controls. Drug synergism was
quantified by calculating the combination index (CI)
based on the multiple drug effect equation. The CI for
each concentration of drugs was calculated by COM-
PUSYN Software (https://www.combosyn.com/) where
the CI value < 0.9 was indicative of synergism.
2.8. Flow cytometry (FACS) analysis
The NCI-H820 cells were seeded into 60-mm culture
dishes (1 9 106 cells/well) and were treated with the
indicated drugs. The treated cells were collected and
washed in phosphate-buffered saline (PBS). The apop-
totic cells were analyzed by FITC Annexin V apopto-
sis Detection Kit (BD Biosciences, San Jose, CA,
USA) according to the manufacturer’s protocol.
Stained cells were analyzed with a FACScan flow
cytometer (Becton Dickinson, Midland, ON, Canada).
2.9. Western blot analysis
Cell lysates were prepared using RIPA buffer (Thermo
Scientific) with protease inhibitor cocktail (Roche) and
phosphatase inhibitor cocktail (Roche, Basel, Switzer-
land), incubated for 15 min on ice and centrifuged at
16 800 g for 10 min at 4 °C. The bicinchoninic acid
(BCA) method (Thermo Scientific, Waltham, MA,
USA) was used to determine the protein concentration.
Proteins were resolved by SDS/PAGE and transferred
to polyvinyl difluoride membrane. After blocking with
5% skim milk, membranes were individually probed
with anti-phospho-AKT (Cell Signaling Technology,
Danvers, MA, USA), anti-phospho-ERK (Cell Signal-
ing Technology), anticleaved caspase 3 (Cell Signaling
Technology), anti-PARP (Cell Signaling Technology),
anti-p21 (Cell Signaling Technology), anti-MDM2 (Cell
Signaling Technology), anti-MDM4 (Cell Signaling
Technology), anti-p53 (Cell Signaling Technology),
anti-PUMA (Cell Signaling Technology), and anti-actin
(Sigma-Aldrich Corporation) antibodies. The mem-
branes were washed and incubated with horseradish
peroxidase-conjugated secondary antibodies, followed
by enhanced chemiluminescence detection according to
the manufacturer’s instructions (ThermoFisher).
2.10. In vivo experiments
All animal procedures were approved by The Jackson
Laboratory Institutional Animal Care and Use
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Committee, protocol 17-0028. The patient-derived
xenograft (PDX) LG1049 lung cancer model contain-
ing the EGFR T790M mutation was purchased from
The Jackson Laboratory (Bar Harbor, Maine). The
surgically resected tissues were minced into pieces
approximately ~ 2 mm in size and injected into the
flanks of NOD/SCID/IL-2c-receptor null (NSG)
female mice. Drug treatments began after tumors
reached approximately 150–200 mm3. Mice were ran-
domly divided into 8 treatment groups consisting of 5
mice in each group: (1) vehicle only, (2) erlotinib only,
(3) nutlin-3 only, (4) erlotinib plus nutlin-3, (5) carfil-
zomib only, (6) erlotinib plus carfilzomib, (7) SJ-
172550, and (8) erlotinib plus SJ-172550. The follow-
ing drugs and dosing schedules were used: erlotinib:
25 mgkg1 diluted in 0.5% methylcellulose solution,
oral gavage daily; nutlin-3 and SJ-172550: 20 mgkg1
diluted in 10% DMSO, 9% ethanol, 27% polyethylene
glycol (PEG) 400, 54% Phosal 50 PG, intraperitoneal
injection once every two days; carfilzomib:
1.5 mgkg1 diluted in 2% DMSO, 30% PEG300, and
2% Tween-80, intravenous injection once a week.
Mouse weight monitoring and sampling were per-
formed as previously described [22].
2.11. Statistical analysis
Statistical analyses were performed using PRISM 4.0
(GraphPad Software, San Diego, CA, USA). Differ-
ences between two variables were assessed by an
unpaired Student’s t-test. An observation was consid-
ered statistically significant if the P-value was less than
0.05.
3. Results
3.1. Genome-scale CRISPR screening for
erlotinib-sensitizing genes identified 81 candidate
target genes
We applied a genetic screening approach to identify
candidate genes whose loss-of-function would lead to
acquired sensitivity to erlotinib in lung cancer cells
that are erlotinib-resistant. The idea was to use a pool
of sgRNA-expressing lentivirus to generate a library of
knockout cells that could be screened for sensitivity to
erlotinib via negative selection (Fig. 1A). We trans-
duced an erlotinib-resistant human lung cancer cell line
(NCI-H820) with the GeCKO v2 library at a multiplic-
ity of infection (MOI) of 0.3. The GeCKO v2 libraries
consisted of 123 411 unique sgRNAs for 19 050 genes
in the human genome [17]. Cells transduced with
lentiviral vectors were maintained with or without
erlotinib for 14 days, and residual sgRNA abundance
was measured by counting sgRNA numbers using
high-throughput sequencing. After 14 days of erlotinib
treatment, the spectrum of sgRNAs incorporated
among the erlotinib-treated cells was significantly dif-
ferent from both erlotinib-treated cells grown for
7 days, and untreated cells (Figs S1A, S1B).
The GeCKO v2 library contains 6 sgRNAs per
gene but the knockout efficiency of each sgRNA was
unknown. Therefore, we analyzed the sgRNA screen-
ing data using two levels of analyses: (1) gene unit
analysis with MAGeCK-VISPR (Fig. 1B) [23] and (2)
sgRNA unit analysis with edgeR (Fig. 1C).
MAGeCK-VISPR estimates the sgRNA abundance
(beta score) at the gene level, taking replicates into
consideration. Positive (or negative) beta scores mean
positive (or negative) selections for the gene at each
condition compared with the control samples at day
0 (D0). Genes with beta scores among the highest or
lowest 2% were selected as highly variable genes, and
these were further subjected to k-means clustering
(k = 4) (Fig. 1B; Table S2). We identified 368 genes
that showed strong negative selection at 14 days of
erlotinib treatment, implying that cells transduced
with sgRNAs for these genes became more sensitive
to erlotinib treatment. Next, we compared the abun-
dance of individual sgRNAs between cells with (E14)
or without erlotinib treatment for 14 days (D14)
using the edgeR program. We identified 4183
sgRNAs for 1945 genes whose abundance was signifi-
cantly reduced in erlotinib-treated cells (false discov-
ery rate < 0.05, log2 FoldChange ≤ 1, and number
of sgRNA reads per gene > 2) (Fig. 1C; Table S3).
Then, we took the intersection of the MAGeCK-
VISPR and edgeR results, which yielded a subset of
81 highly confident erlotinib-sensitizing genes
(Fig. 1D; Table S4). These 81 genes constitute the
main candidate genes whose knockout led to
decreased cell viability after erlotinib treatment, thus
serving as the foundation for identifying new targets
to overcome erlotinib resistance.
3.2. Functional characterization of 81 candidate
genes reveals cell cycle and ubiquitination as key
regulatory processes
In order to understand the overall biological roles of
the putative erlotinib-sensitizing genes, we performed
network and functional analyses for these 81 genes.
An expanded molecular network of protein–protein
interactions was obtained using the StringApp of
Cytoscape [20], and a network topology analysis
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identified a highly connected subnetwork that con-
sisted of genes associated with cell cycle processes and
regulation of protein ubiquitination (Fig. 1E). Nota-
bly, two genes (ANAPC5 and CDK1) out of the 81
candidate genes were related to both biological pro-
cesses, suggesting interplay of the two processes. Simi-
larly, we also performed a gene set enrichment analysis
for these 81 candidate genes using Gene Ontology
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(GO) terms for biological processes in MSigDB
(http://software.broadinstitute.org/gsea/index.jsp),
which again identified mitotic cell cycle and regulation
of protein ubiquitination as enriched processes
(Fig. S2).
We found that 11 (13.1%, P = 0.027) and 7 (8.6%,
P = 0.046) out of 81 genes were assigned to ‘cell cycle
process’ and ‘protein ubiquitination’ GO terms, respec-
tively (Fig. 2A,B). Since our GeCKO library consists of
6 sgRNAs per gene, we examined the rank distribution
of sgRNAs for genes in these two processes to check for
knockout efficiency and consistency of sgRNAs. The
rank position plot showed that the majority of sgRNAs
for these genes were located on the depletion side
(Fig. 2A,B). Thus, our results strongly suggest that
knockout of these genes, involved in cell cycle or protein
ubiquitination, can transform the erlotinib-resistant
tumor cells to become sensitive to erlotinib.
To study the clinical significance of these genes in
the cell cycle process and protein ubiquitination path-
ways, we further performed Kaplan–Meier survival
analyses based on the gene expression level of 492 lung
adenocarcinoma patients from the TCGA database
[24]. We compared the overall survival of patients in
the top vs. bottom quartile of the target gene’s expres-
sion. Among 11 cell cycle process genes and 7 protein
ubiquitination genes, we found that the prognosis was
significantly better (P < 0.05) in patients with lower
expression of three cell cycle-related genes, PCNA,
NUP50, and TUBG1, and one protein ubiquitination
gene, PSMB6 (Fig. 2C). Thus, expression levels of
these genes could serve as potential prognostic markers
in NSCLC.
Additionally, we performed validation experiments
to determine whether loss of the candidate genes con-
tributes to erlotinib sensitivity in the lung cancer cells.
NCI-H820 and NCI-H1975 cells were infected with
lentivirus carrying sgRNAs targeting candidate gene
and treated with various doses of erlotinib. Cell
viability was determined after 3 days to evaluate the
drug resistance. sgRNAs targeting MDM4, PSMA6,
and PSMB6 led to a decrease in mRNA expression
and increased sensibility to erlotinib (Fig. 2D,E). The
IC50 of erlotinib to each sgRNA-transduced cell
increased 13-fold (MDM4), 6.9-fold (PSMA6), and
3.7-fold (PSMB6), respectively, compared to control
cells in NCI-H820 (Fig. 2D). Dose–response curves for
NCI-H1975 cells, transduced with individual targeting
lentiCRISPR, show that loss of MDM4, PSMA6, or
PSMB6 conferred the most significant sensitivity to
erlotinib (Fig. 2E). We also compared to the erlotinib
IC50 for cells that targeted ANAPC5 or CDK1 or
control sgRNA. The erlotinib IC50 was decreased for
each target gene in the respective NCI-H1975 knock-
out cells (Fig. S3).
3.3. Pharmacological inhibition of targets in cell
cycle or ubiquitination pathways exhibited
synergistic effect
The effect of gene knockout by sgRNAs can also be
achieved by chemical inhibitors with sufficient speci-
ficity. To investigate the efficacy of combination thera-
pies to overcome erlotinib resistance, we searched for
chemical inhibitors targeting the 81 candidate genes
from our CRISPR screen. Through extensive literature
and database surveys, thirteen chemical inhibitors were
found to target these candidate genes (Table S5).
Unfortunately, there were no commercial inhibitors
for the two highly confident targets, ANAPC5 and
CDK1, which appear to have functions in both cell
cycle and protein ubiquitination processes. We tested
the drug efficacy and the synergistic effect with erloti-
nib for each of the thirteen chemical inhibitors on the
NCI-H820 lung cancer cell line in an in vitro setting
(Fig. S4A). Six of the inhibitors were shown to affect
cell viability in a dose-dependent manner. Three chem-
icals (N-ethylmaleimide for ACAD8, quinacrine for
Fig. 1. Genome-scale negative selection screening of erlotinib-sensitive related genes. (A) Schematic representation of the loss-of-function
screen using the human genome-scale CRISPR/Cas9 knockout library. D0, D7, and D14 refer to puromycin-selected day 0 cells (D0), control
day 7 cells (D7) with DMSO, and control day 14 cells (D14) with DMSO, respectively. E7 and E14 refer to erlotinib-treated day 7 cells (E7)
and erlotinib-treated day 14 cells (E14), respectively. (B) A heatmap of beta scores from MAGeCK-VISPR on the NCI-H820 knockout dataset.
Using k-means clustering (k = 4), we identified four clusters. Only genes among the highest or lowest 2% b scores in 14-day DMSO or
erlotinib treatment conditions are shown in the heatmap. (C) The MA plot showing enrichment of specific sgRNAs after erlotinib treatment
(M = log2 E14/D14, A = ½log2 E14*D14). Red dots (n = 4183) indicate sgRNAs significantly depleted after 14 days of erlotinib treatment.
(D) Venn diagram showing the overlap of genes depleted between the two methods: MAGeCK-VISPR and edgeR, in the NCI-H820 lung
cancer cell line. The overlapping genes are indicated with the red dots in the beta score plot of E14 data. (E) STRING network analysis with
the 81 commonly depleted genes. Genes involved in the cell cycle process and ubiquitin-dependent protein catabolic process are indicated
in red and blue with colored boundaries, respectively. Gray nodes are the linker genes from the STRING network, which are not
differentially expressed.
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Fig. 2. Loss-of-function screening identifies targets that were depleted in erlotinib resistance cells. (A, B) The rank distribution diagram of
sgRNAs targeting genes associated with cell cycle processes (A) and protein ubiquitination (B). Ranks of sgRNAs (shown as the
background) were obtained from the log2 ratio of the normalized sgRNA counts between the control and erlotinib treatment samples at day
14. The ranks of 6 sgRNAs targeting the gene of interest are shown with red vertical lines. (C) Survival analysis according to gene
expression of candidate genes, using the TCGA-LUAD patient cohort (n = 492). Patient groups of high and low expression indicate the top
(n = 123) and bottom (n = 123) quartiles, respectively, according to gene expression level of interest. P-values were obtained from the log-
rank test. (D) The validation experiments of single CRISPR/Cas9 treatment about candidate gene in NCI-H820 cells. The mRNA expression
levels of target gene were detected by real-time PCR and the sensitivity of erlotinib was determined with dose–response curves. The
erlotinib IC50 decreased for each candidate sgRNA-transduced cell line compared to control sgRNA transduce cell (sgNTC). (E) The knockout
of candidate genes had more effected in other lung cancer cell line NCI-H1975. The IC50 of erlotinib to each sgRNA-transduced cells was
highly decreased in NCI-H1975 cells.
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MB21D1, and bortezomib for PSMA6 and PSMB6)
were effective as a monotherapy with no significant
additional benefits in combination treatments with
erlotinib (Fig. 3A). Three other drugs (SJ-172550 for
MDM4, nutlin-3 for MDM2/MDM4, and carfilzomib
for PSMA6 and PSMB6) showed improved IC50 val-
ues when used as a monotherapy but increased efficacy
when used in combination with erlotinib on NCI-H820
lung cancer cell lines (Fig. 3B). Validation experiments
in another erlotinib-resistant lung cancer cell line,
NCI-H1975, confirmed the synergistic effect of these
latter three inhibitors (i.e., SJ-172550, nutlin-3, and
carfilzomib) with erlotinib (Fig. S4B). Thus, our data
demonstrated that targeting certain genes in the ‘Cell
cycle process’ (MDM4/MDM2 with SJ-172550 and
nutlin-3) and ‘Protein ubiquitination’ GO term
(PSMA6 and PSMB6 with carfilzomib) were effective
in enhancing responsiveness to erlotinib. Interestingly,
we found that the combination of nutlin-3 or carfil-
zomib and osimertinib (3rd-generation inhibitors of
EGFR T790M) were highly effective in EGFR T790M
lung cancer cell line NCI-H1975 (Fig. S5).
3.4. Activation of the p53 pathway with nutlin-3
confers erlotinib sensitivity by inducing cell cycle
arrest and apoptosis
We identified MDM4 as one of the candidate genes
involved in cell cycle (Fig. 2) through our sgRNA
screen. The major function of MDM4 is to suppress
p53 activities by MDM4-p53 interaction. Interestingly,
the MDM4 inhibitor, SJ-172550, and the MDM2 inhi-
bitor, nutlin-3, showed a synergistic effect with erloti-
nib in erlotinib-resistant lung cancer cell lines, NCI-
H820 (Fig. 3B) and NCI-H1975 (Fig. S4B).
We focused on nutlin-3, because the apoptosis effect
was more prominent in the combination of nutlin-3
and erlotinib, compared to SJ-172550 and erlotinib,
based on propidium iodide staining (Figs 4A, S6A).
The combination treatment of erlotinib and nutlin-3
resulted in a significant increase of cleavage of the poly
(ADP-ribose) polymerase (PARP) and caspase 3
(Fig. 4B), which are characteristics of apoptotic cell
death. In addition, the combination of erlotinib and
nutlin-3 increased the expression of the p21 protein
Fig. 3. Cytotoxicity of erlotinib and three chemical inhibitors. (A) N-ethylmaleimide, quinacrine, and bortezomib effectively inhibited the
growth of erlotinib-resistant NCI-H820, with or without erlotinib. (B) SJ-172550, nutlin-3, and carfilzomib show a synergistic effect with
erlotinib. Erlotinib-resistant NCI-H820 cells were used in viability assays. WST assays were used to examine the cell viability. Data are
represented as mean values  standard error of mean (SEM) based on triplicate experiments, and the regression lines were calculated by
dose–response inhibition models in PRISM 5.0. Combination index (CI) values were calculated at applied concentrations, and the pound signs
represent synergistic effect of the two drugs (#, CI < 0.9; ##, CI < 0.6; ###, CI < 0.3).
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(Fig. 4C), which is a strong inducer of cell cycle arrest
and increased PUMA (p53 upregulated modulator of
apoptosis) expression (Fig. 4C), which is a pro-apop-
totic protein which induces apoptosis by inhibiting
anti-apoptotic Bcl-2 family proteins [25]. The expres-
sion of PUMA is already known to be regulated by
p53 and is involved in p53-dependent and p53-inde-
pendent apoptosis induced by a variety of signals, ulti-
mately leading to cell death [26]. Taken together,
activation of the p53 pathway with nutlin-3 appears to
augment the response of erlotinib by inducing both
cell cycle arrest and apoptosis via p21 and PUMA
induction, respectively (Fig. 4C). Additionally, we con-
firmed that the molecular phenotype in MDM4 knock-
out cells mimics the phenotype in nutlin-3-treated cells
in erlotinib-treated condition (Fig. S6B). A pro-apop-
totic protein PUMA expression was increased in erloti-
nib-treated MDM4 knockout cell.
Fig. 4. Synergistic effect of erlotinib and target gene’s inhibitor in the erlotinib-resistant lung cancer cell line, NCI-H820. (A) The combination
of erlotinib and nutlin-3 increases cell death, as demonstrated by flow cytometry analysis and (B) cleavage of poly (ADP-ribose) polymerase
(PARP) and caspase 3 expression in NCI-H820 cells. (C) Activation of the p53 pathway with nutlin-3 augmented erlotinib response by
inducing apoptosis via PUMA expression. (D) Combination of erlotinib and carfilzomib increases cell death demonstrated by flow cytometry
analysis and (E) cleavage of caspase-3, phospo-AKT, and phosphor-ERK protein expression. All experiments were performed in duplicate,
each being repeated at least two times.
496 Molecular Oncology 15 (2021) 487–502 ª 2020 The Authors. Molecular Oncology published by John Wiley & Sons Ltd
on behalf of Federation of European Biochemical Societies
Strategies for overcoming resistance to EGFR inhibitor erlotinib J. Lee et al.
Carfilzomib and erlotinib combination treatments
also showed synergistic effects in apoptotic cell death
(Fig. 4D). The increase of cell death (17.2% to
49.2%; 2.86-fold) was higher in combination therapy
compared to monotherapies with erlotinib (17.2% to
22.4%; 1.30-fold) or carfilzomib alone (17.2% to
39.0%; 2.27-fold). Additionally, the cleavage of cas-
pase 3 in NCI-H820 cells was increased dramatically
during combination treatments with both erlotinib
and carfilzomib compared to erlotinib or carfilzomib
treatments alone (Fig. 4E). Interestingly, phosphory-
lation of AKT and ERK was significantly decreased
for the combination treatment on NCI-H820 cells
(Fig. 4E). Phosphorylated AKT and ERK inhibit
apoptosis and induce cell survival through phospho-
rylation of various proteins such as Bad, GSK3b,
caspase 9, and FoxO transcription factors [27]. These
results suggest that the combination treatment with
erlotinib and carfilzomib also synergistically induces
cell death in erlotinib-resistant cells.
3.5. Synergistic effects of erlotinib-sensitizing
chemicals were validated in in vivo patient-
derived xenografts (PDXs) mouse models
To further study these three putative erlotinib-sensitiz-
ing chemicals (SJ-172550, nutlin-3, and carfilzomib),
we performed efficacy testing with a human lung can-
cer PDX model having an EGFR T790M mutation
(i.e., comprised of erlotinib-resistant cells). The
LG1049 PDX was implanted in immunodeficient NSG
mice and subsequently treated with erlotinib, SJ-
172550, nutlin-3, or carfilzomib as well as with treat-
ments combining erlotinib with SJ-172550, nutlin-3, or
carfilzomib. Nutlin-3 and carfilzomib both showed sig-
nificant cell death when used alone or in combination
with erlotinib (Fig. 5A,B) but treatment with SJ-
172550 alone did not show a significant tumor inhibi-
tory growth effect in these in vivo experiments
(Fig. S7). The combination of erlotinib with nutlin-3
or carfilzomib increased apoptosis signals by cleaved
caspase 3 staining (Fig. 5C). These results are in good
concordance with the previous in vitro cell experiment
data for both monotherapy and combination treat-
ments. Taken together, combinatorial inhibition of
nutlin-3 and erlotinib or carfilzomib and erlotinib was
effective in tumor growth inhibition of an erlotinib-re-
sistant lung cancer PDX.
4. Discussion
A pooled CRISPR-Cas sgRNA library screen can pro-
vide new opportunities to systematically identify new
targets for drug resistance. We conducted a large-scale
loss-of-function screen in a lung cancer cell line, using
this CRISPR-Cas9 system, to find new genes associ-
ated with erlotinib responsiveness and to understand
mechanisms underlying resistance to this drug.
In this study, we identified two major pathways that
contribute to erlotinib resistance. The first target path-
way was cell cycle processes. It is known that p53 is
eventually involved in cancer development by stimulat-
ing or inhibiting cell cycle regulators, so it is very
important to understand the cell cycle regulatory pro-
cesses leading to cancer development.
The mutations of TP53 gene were a negative prog-
nostic factor for overall survival (OS) of advanced
non-small-cell lung cancer (NSCLC) patients, and, in
EGFR-mutated patients, additional mutations of
TP53 gene were associated with shorter OS [28]. In
addition, in EGFR-mutated NSCLC, comutation of
TP53, especially missense mutations, exhibited the
trend toward shorter progression-free survival on
EGFR tyrosine kinase inhibitors (TKIs) [29], suggest-
ing that functional p53 is associated with the respon-
siveness of EGFR-TKIs. In molecular levels,
functional p53 was reported to enhance another
EGFR inhibitor, gefitinib-induced growth arrest
through the up-regulation of Fas in lung cancer cells
[30]. These previous reports suggest that cell cycle reg-
ulation by functional p53 plays considerable roles in
the determination of the responsiveness to erlotinib.
Nutlin-3 is a small molecule inhibitor of the MDM2/
p53 interaction, which leads to nongenotoxic p53 sta-
bilization as well as activation of cell cycle arrest and
apoptosis pathways [31]. Since the discovery of the
nutlins in 2004, several compounds have been devel-
oped and shown to target the p53-MDM2/4 axis by
inhibiting MDM2 and/or MDM4 [32]. Nutlin-3 has a
synergistic cytotoxic effect when used in combination
with TNF-related apoptosis-inducing ligand (TRAIL),
bortezomib, and cisplatin to induce p53-dependent
tumor cell apoptosis in NSCLC [33,31]. Nutlin-3 pref-
erentially sensitizes wild-type p53-expressing cancer
cells such as the A549 lung cancer cell line [34], but
our study shows that it also appears to work in
mutant p53-expressing cancer cells (TP53 T284P in the
NCI-H820 cell line; TP53 R273H in the NCI-H1975
cell line; and TP53 P72R in the LG1049 PDX model).
In addition, nutlin-3 synergizes with erlotinib in both
an erlotinib-resistant lung cancer cell lines NCI-H820,
NCI-H1975, and in vivo in an erlotinib-resistant lung
cancer PDX model (Fig. 3B and Fig. 5A). The
MDM4 inhibitor, SJ-172550, also showed synergistic
cell death when used in combination with erlotinib in
an in vitro assay but this synergistic effect was not
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Fig. 5. In vivo efficacy of erlotinib-based combination treatment with nutlin-3 or carfilzomib in EGFR T790M mutated patient-derived
xenografts. Tumor volumes of each group’s mice (N = 5) are shown on the left and their tumor mass after 28 days of treatment are shown
on the right. (A) The synergistic effect of erlotinib and nutlin-3 in lung adenocarcinoma mouse models with the EGFR T790M mutation
(LG1049). A significant effect upon tumor growth was observed with combinations of erlotinib and nutlin-3 (2-way ANOVA: **, P = 0.0069)
when compared with nutlin-3 only. Similarly, when the mass of the tumors at endpoint were compared, the combinations of erlotinib and
nutlin-3 (unpaired t-test: **, P = 0.0014) showed significant improvement over nutlin-3. (B) The synergistic effect of erlotinib and carfilzomib
in lung adenocarcinoma mouse models with the EGFR T790M mutation (LG1049). A significant effect upon tumor growth was observed
with combinations of erlotinib and carfilzomib (2-way ANOVA: ***, P < 0.0001) when compared with carfilzomib only. Similarly, when the
mass of the tumors at endpoint were compared, the combinations of erlotinib and carfilzomib (unpaired t-test: ***, P < 0.0001) showed
significant improvements over carfilzomib alone. Graphs represent mean  SD of the experiments. (C) Representative H&E-stained section
and IHC against the apoptosis marker cleaved caspase-3 of representative tumors from each of the treatment groups; scale bar, 300 lm.
The xenografts that have been treated with a combination of erlotinib and nutlin-3 or erlotinib and carfilzomib showed increased cleaved
caspase 3 expression.
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reproduced in vivo in mouse drug tests (Fig. S5). Iden-
tifying inhibitors specific to ubiquitin-proteasome path-
ways is usually of great interest for cancer treatment
because aberrations in the components of this pathway
are commonly observed in many cancers and uncon-
trolled growth of cancer cells can result either from
stabilization of oncoproteins (e.g., c-jun) or increased
degradation of tumor suppressor proteins (e.g., p53).
Protein ubiquitination and proteasomal pathway are
an evolutionary conserved process for protein degrada-
tion, and crucial for biological processes, including cell
survival and differentiation [35]. Several tumor-pro-
moting or suppressing pathways, including NF-jB,
HIF-1a, and p53 pathways, are regulated through pro-
tein ubiquitination processes [35]. The EGFR protein
itself was regulated via ubiquitinated, and deubiquiti-
nating enzyme, ubiquitin-specific protease 22 (USP22)
was associated with EGFR-TKI resistance by enhanc-
ing EGFR stability [36]. Inhibition of the ubiquitin-
proteasome pathway exerts antitumor effect by regu-
lating several key pathways, including inhibition of
NF-jB pathway via increase of I-jB, inhibition of cell
cycle via increase of p53 and cyclins, and increase of
apoptosis via increased of p53-mediated Bax protein
[37], and these pathways are associated with the
responsiveness to EGFR-TKIs [30,38]. Carfilzomib is a
second-generation anticancer drug acting as a selective
proteasome inhibitor. It irreversibly binds and inhibits
the chymotrypsin-like activity of the 20S proteasome,
an enzyme that degrades unwanted cellular proteins.
Inhibition of proteasome-mediated protein ubiquitina-
tion results in a buildup of polyubiquitinated proteins,
which is thought to cause cell cycle arrest, apoptosis,
and inhibition of tumor growth [39,40]. Carfilzomib
was approved by the U.S. FDA in 2012 for multiple
myeloma patients who have received at least two prior
therapies, including treatment with bortezomib and an
immunomodulatory therapy (such as lenalidomide),
and have demonstrated disease progression on or
within 60 days of completion of the last therapy [39].
Furthermore, the U.S. FDA has approved carfilzomib,
in combination with other anticancer drugs, to treat
patients with relapsed multiple myeloma. However, its
efficacy has not yet been tested in clinical trials of lung
cancer. Here, we show that a combination treatment
using erlotinib and carfilzomib could efficiently induce
apoptosis of erlotinib resistance lung cancer cells.
Over the years, various trials have been attempted
to identify new drugs to overcome erlotinib resistance.
For example, a second-generation EGFR-TKI, an irre-
versible inhibitor that contains a Michael-acceptor
group and covalently attaches to the EGFR ATP
binding site, may act as a pan-HER inhibitor that also
inhibits EGFR, HER2, and HER4 [41]. Additionally,
a third-generation EGFR inhibitor that specifically
responds to T790M EGFR, such as osimertinib, has
been recently approved by the U.S. FDA [42]. More-
over, mutant EGFR, including T790M, is more sensi-
tive to an inhibitor of the heat-shock protein 90
(HSP90) than normal EGFR carrying cells [43]. Thus,
combination of an HSP90 inhibitor and TKI could be
another way to effectively overcome T790M resistance.
Finally, animal studies using T790M transgenic mice
have shown that the combination of EGFR blocking
antibodies cetuximab and BIBW2992 can also be effec-
tive in overcoming T790M resistance [44]. Although
third-generation inhibitors are available in the clinic,
lst-generation EGFR-TKIs, such as erlotinib and gefi-
tinib, are still widely used in first-line treatment of
NSCLC patients with EGFR mutations. In addition,
candidate chemicals from our screening showed syner-
gistic effect with 3rd-generation inhibitor, osimertinib
in some EGFR-mutated NSCLC cells (Fig. S5), sug-
gesting that our screens are probably applicable for
enhancing the effect of 3rd-generation inhibitors.
5. Conclusions
Erlotinib is highly effective in lung cancer patients with
EGFR mutations. However, despite initial favorable
responses, many patients develop erlotinib resistance.
Here, we applied a CRISPR/cas9 library screen to iden-
tify five genes (MDM4, PSMA6, PSMB6, ANAPC5,
and CDK1) that are associated with erlotinib respon-
siveness and have provided evidence that inhibitors for
two of these genes (nutlin-3 for MDM4 or carfilzomib
for PSMA6 and PSMB6) can be used in combination
treatments with erlotinib to potentially minimize the
development of erlotinib resistance. We hypothesize
that targeting cell cycle processes with nutlin-3, or pro-
tein ubiquitination processes with carfilzomib, might be
promising new clinical strategies to overcome resistance
to EGFR inhibitor drugs in NSCLC.
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Fig. S1. CRISPR/cas9 screening results of all condi-
tions.
Fig. S2. Gene Ontology (GO) analysis using MSigDB.
Fig. S3. Validation experiments on selected two genes,
ANAPC5 and CDK1.
Fig. S4. The test of drug efficacy and the synergistic
effect with erlotinib for each of the thirteen chemical
inhibitors on the NCI-H820 lung cancer cell line in an
in vitro setting.
Fig. S5. Synergistic effect of 3rd generation TKIs inhi-
bitor osimertinib and nutlin-3 or carfilzomib in the
erlotinib resistant lung cancer cell line NCI-H1975.
Fig. S6. Synergistic effect of erlotinib and SJ-172550 in
the erlotinib resistant lung cancer cell line, NCI-H820.
Fig. S7. In vivo efficacy of erlotinib-based combination
treatment with SJ-172550 in EGFR T790M mutated
patient-derived xenografts.
Table S1. The sgRNA sequence for target gene valida-
tion.
Table S2. The beta score from MAGeCK-VISPR pro-
gram for highly variable genes used in k-means cluster-
ing.
Table S3. List of 1945 genes with differentially
expressed sgRNAs at day 14.
Table S4. The MAGeck-VISPR and EdgR analysis
showed a subset of 81 genes.
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